The Billion Cell Atlas, backed by Eli Lilly, MSD and AstraZeneca, maps mechanisms to support informed drug discovery and ...

Illumina unveiled the Billion Cell Atlas, a large‑scale genetic perturbation dataset built with pharma partners to advance AI‑powered drug discovery, target validation, and disease biology.

Under an alliance framework with AstraZeneca, Merck, and Eli Lilly and Company leading as founding participants, the Atlas is ...

The field of cancer immunotherapy has achieved remarkable progress, introducing strategies such as immune checkpoint inhibitors and adoptive cell therapies ...

Explore the groundbreaking AI genomics platform, Inference, launched by Variant Bio to enhance drug discovery using genetic ...

Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine, today announced ...

Organoids have now evolved beyond simple experimental models to become next-generation biological platforms that precisely replicate human organ ...

Stress during pregnancy such as gut changes or a trigger of the immune system can impact the brain health of the foetus, ...

Frost & Sullivan is pleased to announce that BostonGene has been recognized for 2025 Global Technology Innovation Leadership in the ...

How AI, robotics, and modular design are transforming single-cell and spatial biology into scalable, precision-driven engines of discovery.

Demonstrates how dual-purpose therapeutic targets may address both hepatocellular carcinoma progression and cellular ...

Novel research led by Brazilian scientists describes the immune system's reactions in detail in the first living patient to ...